Eli Lilly on Thursday said its next-generation obesity drug retatrutide cleared its first late-stage trial on Type 2 diabetes patients, helping them manage their blood sugar levels and lose weight
Patients taking 9mg and 12mg of retatrutide lost an average of 64.4lb (25.9%) and 70.3lb (28.3%), respectively
They also slow stomach emptying more effectively, helping to decrease overall food intake
This resembles one of the two mechanisms reviewed above by which riluzole appears to reduce glutamate levels (Pittenger, Coric et al., 2008)
When used together, Ipamorelin and CJC-1295 act synergistically, amplifying the effects of each other, resulting in increased growth hormone production and release
Basis for its hypocholesterolemic effect